

# E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020

<https://marketpublishers.com/r/E45127E78E85EN.html>

Date: February 2020

Pages: 101

Price: US\$ 3,500.00 (Single User License)

ID: E45127E78E85EN

## Abstracts

E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020

### SUMMARY

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - E3 ubiquitin-protein ligase Mdm2 is a protein encoded by the MDM2 gene. It acts as an ubiquitin ligase E3 toward itself and ARRB1. It permits the nuclear export of p53/TP53. It promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma RB1 protein. It inhibits DAXX-mediated apoptosis by inducing its ubiquitination and degradation.

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) pipeline Target constitutes close to 29 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 2, 8 and 2 respectively. Similarly, the universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively.

Report covers products from therapy areas Oncology, Ophthalmology, Musculoskeletal Disorders and Toxicology which include indications Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Liposarcoma, Lymphoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Glioblastoma Multiforme (GBM), Leukemia, Metastatic Breast Cancer, Myelodysplastic Syndrome, Osteosarcoma, Soft Tissue Sarcoma, Metastatic Melanoma, Polycythemia Vera, Post-Essential

Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Adenoid Cystic Carcinoma (ACC), B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia), Brain Tumor, Breast Cancer, Chemotherapy Induced Myelosuppression, Colorectal Cancer, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Dry (Atrophic) Macular Degeneration, Essential Thrombocythemia, Follicular Lymphoma, Hepatic (Liver) Tumor, Hepatocellular Carcinoma, Lung Cancer, Melanoma, Merkel Cell Carcinoma, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Neuroblastoma, Non-Small Cell Lung Cancer, Osteoarthritis, Pancreatic Cancer, Primary Myelofibrosis, Proliferative Vitreoretinopathy (PVR), Retinoblastoma, Salivary Gland Cancer, Sarcomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Well Differentiated Liposarcoma.

The latest report E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020, outlays comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)

The report reviews E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein

or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects

The report assesses E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or

Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

### Introduction

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Overview

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics

### Development

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Therapeutics Assessment

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Companies Involved in Therapeutics Development

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Drug Profiles

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Products

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Product Development

### Milestones

### Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020  
Number of Products under Development by Therapy Areas, H1 2020  
Number of Products under Development by Indications, H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020  
Number of Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Companies, H1 2020 (Contd..2), H1 2020  
Products under Development by Companies, H1 2020 (Contd..3), H1 2020  
Products under Development by Companies, H1 2020 (Contd..4), H1 2020  
Number of Products under Investigation by Universities/Institutes, H1 2020  
Products under Investigation by Universities/Institutes, H1 2020  
Number of Products by Stage and Mechanism of Actions, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Pipeline by Aileron Therapeutics Inc, H1 2020  
Pipeline by Amgen Inc, H1 2020  
Pipeline by Ascentage Pharma Group International, H1 2020  
Pipeline by Astex Pharmaceuticals Inc, H1 2020  
Pipeline by Astex Therapeutics Ltd, H1 2020  
Pipeline by Boehringer Ingelheim International GmbH, H1 2020  
Pipeline by Daiichi Sankyo Co Ltd, H1 2020  
Pipeline by F. Hoffmann-La Roche Ltd, H1 2020  
Pipeline by Focal Point Pharmaceuticals Inc, H1 2020  
Pipeline by Kartos Therapeutics Inc, H1 2020  
Pipeline by Merck & Co Inc, H1 2020  
Pipeline by MiRx Pharmaceuticals LLC, H1 2020  
Pipeline by Novartis AG, H1 2020  
Pipeline by Oncopia Therapeutics LLC, H1 2020  
Pipeline by Seak Therapeutics LLC, H1 2020  
Pipeline by Unity Biotechnology Inc, H1 2020  
Dormant Products, H1 2020  
Dormant Products, H1 2020 (Contd..1), H1 2020  
Dormant Products, H1 2020 (Contd..2), H1 2020

Discontinued Products, H1 2020

Discontinued Products, H1 2020 (Contd..1), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Aileron Therapeutics Inc

Amgen Inc

Ascentage Pharma Group International

Astex Pharmaceuticals Inc

Astex Therapeutics Ltd

Boehringer Ingelheim International GmbH

Daiichi Sankyo Co Ltd

F. Hoffmann-La Roche Ltd

Focal Point Pharmaceuticals Inc

Kartos Therapeutics Inc

Merck & Co Inc

MiRx Pharmaceuticals LLC

Novartis AG

Oncopia Therapeutics LLC

Seak Therapeutics LLC

Unity Biotechnology Inc



## I would like to order

Product name: E3 Ubiquitin Protein Ligase Mdm2 - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/E45127E78E85EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E45127E78E85EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970